Key Metrics
12.9
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.01 - 0.05
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
5 - 10
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.94
5-Year SI
5-year SI
- N/A 2-year SI
- 0.93 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Drug Discovery
SJR
- Q1 Drug Discovery
- Q1 Molecular Medicine
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.42
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
6 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
10%
4 to 6 months
48%
7 to 9 months
26%
Above 9 months
17%
Did you find this useful?
Thank you for your feedback.
Indexed in the following public directories
-
Web of Science -
Scopus -
DOAJ -
SJR
Topics Covered
- Lung
- Oligonucleotide
- Breast cancer
- Skeletal muscle
- Lung cancer
- Virus
- Functional recovery
- Hepatocellular carcinoma
- Gene expression
- RNA-binding protein
- Pulmonary hypertension
- Myocardial infarction
- Extracellular vesicles
- Irradiation
- Autophagy
- Immune cell infiltration
- Transcription factor
- Colorectal cancer
- Subcutaneous injection
- Osteosarcoma
Journal Specifications
| Overview | |
| Publisher | CELL PRESS |
| Language | English |
| Frequency | Quarterly |
| Article Processing Charges | USD 3900 |
| Publication Time | 20 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | American Society of Gene & Cell Therapy |
| Frequency | Quarterly |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Waiver Policy | Visit website |
| Publication Time | 20 |
| Article Processing Charges | USD 3900 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
Planning to publish in Molecular Therapy - Nucleic Acids ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Allele-specific CRISPR-Cas9 editing inactivates a single-nucleotide variant associated with collagen VI muscular dystrophy
- 10 Dec 24
- Molecular Therapy - Nucleic Acids
-
Full paper
CRISPR-Cas13d: RNA’s own Jedi Master in the fight against viral darkness
- 10 Dec 24
- Molecular Therapy - Nucleic Acids
-
Full paper
Boosting CRISPR-Cas9 efficiency through enhanced homologous recombination
- 1 Dec 24
- Molecular Therapy - Nucleic Acids
-
Full paper
Messing up with the regulator: A rational AI-driven drug design strategy to disrupt miRNA-target interactions
- 1 Dec 24
- Molecular Therapy - Nucleic Acids
-
Full paper
A modular platform for nucleic acid-driven multimerization of nanobodies for advanced molecular imaging
- 1 Dec 24
- Molecular Therapy - Nucleic Acids
-
Full paper
Reading through the nonsense: Gentamicin and ELX-02 as rescuing therapies for epidermolysis bullosa
- 1 Dec 24
- Molecular Therapy - Nucleic Acids
Scite analysis
Powered by scite_
2.7k articles received 66.4k citations see all
- 1,723 Supporting
- 64,206 Mentioning
- 129 Contrasting
Editorial notices
- 79 Retractions
- 1 Withdrawals
- 0 Corrections
- 120 Errata
- 3 Expression of Concern
FAQs
How long has Molecular Therapy - Nucleic Acids been actively publishing?
Molecular Therapy - Nucleic Acids has been in operation since 2012 till date.
What is the publishing frequency of Molecular Therapy - Nucleic Acids ?
Molecular Therapy - Nucleic Acids published with a Quarterly frequency.
How many articles did Molecular Therapy - Nucleic Acids publish last years ?
In 2023, Molecular Therapy - Nucleic Acids published 301 articles.
What is the eISSN & pISSN for Molecular Therapy - Nucleic Acids ?
For Molecular Therapy - Nucleic Acids,eISSN is 2162-2531 and pISSN is2162-2531.
What is Citescore for Molecular Therapy - Nucleic Acids ?
Citescore for Molecular Therapy - Nucleic Acids is 12.9.
What is SNIP score for Molecular Therapy - Nucleic Acids ?
SNIP score for Molecular Therapy - Nucleic Acids is 1.42.
What is the SJR for Molecular Therapy - Nucleic Acids ?
SJR for Molecular Therapy - Nucleic Acids is Q1.
Who is the publisher of Molecular Therapy - Nucleic Acids ?
CELL PRESS is the publisher of Molecular Therapy - Nucleic Acids.